Pliant posts high-dose data of oral IPF drug with 'quite favorable' safety, outlines trial plans
Pliant Therapeutics reported Monday morning that patients who got the high dose of its oral drug for idiopathic pulmonary fibrosis, or IPF, saw their disease stabilize. Importantly, Pliant noted its drug came with few treatment-related adverse events in a field where approved options have substantial side effects.
The early data sent Pliant’s stock $PLRX up 50%, from around $22 to nearly $35 a share.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.